4.7 Article

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

期刊

CANCER DISCOVERY
卷 11, 期 12, 页码 2998-3007

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-21-0425

关键词

-

类别

资金

  1. Checkmate Pharmaceuticals, Inc.
  2. Parker Institute for Cancer Immunotherapy
  3. UCLA Tumor Immunology Training Grant [NIH T32CA009120]
  4. Cancer Research Institute Irvington Postdoctoral Fellowship Program
  5. [R35 CA197633]

向作者/读者索取更多资源

In patients with advanced melanoma, combining intratumoral TLR9 agonist vidutolimod with pembrolizumab showed promising clinical activity and manageable safety profile, indicating potential to overcome resistance to PD-1 blockade through IFN response induction.
Patients with advanced melanoma that is resistant to PD-1 blockade therapy have limited treatment options. Vidutolimod (formerly CMP-001), a virus-like particle containing a CpG-A Toll-like receptor 9 (TLR9) agonist, may reverse PD-1 blockade resistance by triggering a strong IFN response to induce and attract antitumor T cells. In the dose-escalation part of this phase Ib study, vidutolimod was administered intratumorally at escalating doses with intravenous pembrolizumab to 44 patients with advanced melanoma who had progressive disease or stable disease on prior anti-PD-1 therapy. The combination of vidutolimod and pembrolizumab had a manageable safety profile, and durable responses were observed in 25% of patients, with tumor regression in both injected and noninjected lesions, including visceral lesions. Patients who responded to vidutolimod and pembrolizumab had noninflamed tumors at baseline and induction of an IFN gamma gene signature following treatment, as well as increased systemic expression of the IFN-inducible chemokine CXCL10. SIGNIFICANCE: In this phase Ib study in patients with advanced melanoma, intratumoral TLR9 agonist vidutolimod in combination with pembrolizumab had a manageable safety profile and showed promising clinical activity, supporting the further clinical development of vidutolimod to overcome PD-1 blockade resistance through induction of an IFN response.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据